GlassScriptPhysician profile
Young G In
NPI 1215933684
$5,803.68
in general payments reported to CMS, 2019-2025
23 companies · $444 in 2025
The $444 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,708 · 2020: $643 · 2021: $1,083 · 2022: $986 · 2023: $443 · 2024: $497 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,364 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,363.76 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $925.29 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $914.32 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $617.37 | 2022-2025 | |
| Abbvie INC. | $572.57 | 2020-2025 | |
| Novo Nordisk INC | $553.13 | 2019-2024 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $427.47 | 2019-2023 | |
| Pfizer INC. | $409.37 | 2019-2025 | |
| Allergan, INC. | $213.99 | 2019-2020 | |
| Amarin Pharma, INC. | $194.19 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $176.25 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.36 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $117.68 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $117.05 | 2022-2025 | Zoryve |
| Lilly USA, LLC | $89.46 | 2020-2024 | Jardiance, Mounjaro |
| Sunovion Pharmaceuticals INC. | $86.76 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $51.07 | 2024-2025 | |
| Ironwood Pharmaceuticals, INC | $49.53 | 2019-2024 | |
| Vertex Pharmaceuticals Incorporated | $25.54 | 2025 | |
| Eisai INC. | $21.10 | 2021 | |
| Avanir Pharmaceuticals, INC. | $18.74 | 2019 | |
| Dexcom, INC. | $18.05 | 2024 | Dexcom G6 Transmitter |
| Amgen INC. | $17.22 | 2021 | |
| Mylan Specialty L.P. | $14.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Young In listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.